The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma

Viktoria Laszlo¹,² · Zsuzsanna Valko¹,³ · Judit Oszvar¹ · Ildiko Kovacs³ · Tamas Garay⁴ · Mir Alireza Hoda¹ · Thomas Klukovits¹ · Paul Stockhammer¹,⁵ · Clemens Aigner⁵ · Marion Gröger⁶ · Walter Klepetko¹ · Walter Berger⁷ · Michael Grusch⁷ · Jozsef Tovari⁸,⁹ · Irene C. Waizenegger¹⁰ · Balazs Dome¹,³,¹¹ · Balazs Hegedus¹,⁴,⁵

Received: 12 June 2018 / Revised: 16 November 2018 / Accepted: 19 November 2018 / Published online: 11 December 2018
© The Author(s) 2018

Abstract
No tyrosine kinase inhibitors are approved for malignant pleural mesothelioma (MPM). Preclinical studies identified focal adhesion kinase (FAK) as a target in MPM. Accordingly, we assessed the novel, highly selective FAK inhibitor (BI 853520) in 2D and 3D cultures and in vivo. IC₅₀ values were measured by adherent cell viability assay. Cell migration and 3D growth were quantified by video microscopy and spheroid formation, respectively. Phosphorylation of FAK, Akt, S6, and Erk was measured by immunoblot. The mRNA expression of the putative tumor stem cell markers SOX2, Nanog, CD44, ALDH1, c-myc, and Oct4 was analyzed by qPCR. Cell proliferation, apoptosis, and tumor tissue microvessel density (MVD) were investigated in orthotopic MPM xenografts. In all 12 MPM cell lines, IC₅₀ exceeded 5 μM and loss of NF2 did not correlate with sensitivity. No synergism was found with cisplatin in adherent cells. BI 853520 decreased migration in 3 out of 4 cell lines. FAK phosphorylation was reduced upon treatment but activation of Erk, Akt, or S6 remained unaffected. Nevertheless, BI 853520 inhibited spheroid growth and significantly reduced tumor weight, cell proliferation, and MVD in vivo. BI 853520 has limited effect in adherent cultures but demonstrates potent activity in spheroids and in orthotopic tumors in vivo. Based on our findings, further studies are warranted to explore the clinical utility of BI 853520 in human MPM.

Key messages
• Response to FAK inhibition in MPM is independent of NF2 expression or histotype.
• FAK inhibition strongly interfered with MPM spheroid formation.
• BI 853520 has been shown to exert anti-tumor effect in MPM.

Balazs Dome and Balazs Hegedus contributed equally to this work.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00109-018-1725-7) contains supplementary material, which is available to authorized users.

1 Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
2 Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria
3 Department of Tumor Biology, National Korányi Institute of Pulmonology, Budapest, Hungary
4 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
5 Department of Thoracic Surgery, Ruhrlandklinik, University Clinic Essen, University Duisburg-Essen, Tüscher Weg 40, 45239 Essen, Germany
6 Core Facility Imaging, Medical University of Vienna, Vienna, Austria
7 Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Vienna, Austria
8 Department of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary
9 KINETO Lab Ltd, Budapest, Hungary
10 Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
11 Department of Thoracic Surgery, National Institute of Oncology-Semmelweis University, Budapest, Hungary
Keywords Mesothelioma · Focal adhesion kinase · Tyrosine kinase inhibitor · Angiogenesis · Spheroid formation · Orthotopic xenograft

Introduction

Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy with a strong link to prior asbestos exposure. Invasive growth, locoregional spread, and frequent local recurrence are considered to be responsible for its dismal overall survival (OS), which ranges from 9 to 14 months [1]. Despite the modest OS benefit achieved by adding bevacizumab to standard cisplatin plus pemetrexed chemotherapy [2], no other molecularly targeted drugs could so far enter the clinical practice for this fatal malignancy. Focal adhesion kinase (FAK), also known as protein tyrosine kinase 2 (PTK2), is a ubiquitously expressed 125-kDa non-receptor tyrosine kinase which consists of three distinct domains: a central catalytic domain, a C-terminal FAT domain, and an N-terminal FERM domain [3, 4]. FAK is located in the cytosol, where it is particularly prominent in focal adhesions that interact with different extracellular matrix components [5]. Accordingly, during homeostatic conditions, FAK activation mainly relies on signals from integrins and growth factor receptors, leading to autophosphorylation of the Y397 site in the N-terminal domain [3, 4, 6–8]. FAK overexpression has been preferentially linked to a more aggressive tumor behavior, particularly by promoting tumor cell proliferation, survival, motility, invasion, stem cell renewal, angiogenesis, and metastasis [4, 6, 7, 9–11]. In this context, there is emerging evidence for a functional role of FAK gene amplification and protein overexpression during tumor progression in different tumor types including lung, breast, colorectal, thyroid, kidney, and pancreatic cancers as well as astrocytoma and osteosarcoma [10, 12–14]. Of note, recent studies demonstrated that FAK activation is an important regulator of the immunosuppressive tumor microenvironment and thus promotes immune evasion in murine models of squamous cell carcinoma and pancreatic cancer [15, 16].

Recognition of the crucial role of FAK in the aforementioned tumor promoting functions prompted the development of FAK small molecule inhibitors and their application for cancer therapy [3, 6, 9, 14]. Early preclinical data provided a clear scientific rationale for the anti-tumorigenic effects mediated by FAK inhibitors, though concerns were raised about their potential toxicity via interacting with ATP binding sites on other tyrosine kinases [3]. This led to the development of novel small molecules with high selectivity for FAK which can prevent the autophosphorylation [3, 11]. These ATP-competitive small molecule inhibitors are effective in preclinical models representing a variety of malignancies including MPM [17–19].

Merlin, a frequently inactivated tumor suppressor protein in MPM, is encoded by the neurofibromatosis type 2 (NF2) gene [20]. Merlin-deficient MPMs exhibit increased FAK expression and tumor cell invasion [21, 22]. In a recent clinical phase I study, MPM patients progressing rapidly on prior treatments showed prolonged stable disease when treated with GSK2256098, a specific FAK inhibitor. Interestingly, in this study, patients with merlin-deficient tumors had a significantly better progression-free survival (PFS) than those with merlin-positive tumors [23]. Another study showed similarly better PFS in an advanced MPM patient with unknown merlin status treated with VS-6063, also known as defactinib [24]. These clinical studies are in line with in vitro data, where the FAK inhibitor VS-4718 prominently reduced proliferation and triggered apoptosis in merlin-deficient tumor cells [19]. Notably, Kato et al. reported that E-cadherin expression is a predictive biomarker for VS-4718 FAK in merlin-negative MPM patients [25]. However, a recent phase 2, double-blinded, placebo-controlled study (COMMAND) investigating another FAK inhibitor (VS-6063) in MPM patients randomized by merlin status of the tumor had to be prematurely stopped due to futility (NCT01870609).

Based on these controversial studies, further preclinical investigations are necessary to better understand the interplay between FAK and E-cadherin functions particularly in MPM and, furthermore, to identify novel markers that help to stratify patients for FAK inhibitor susceptibility.

BI 853520 is a novel highly specific FAK inhibitor that has previously demonstrated a good oral bioavailability in mice and led to tumor growth inhibition in a panel of 21 different human carcinomas and in human fibrosarcoma at doses as low as 6 mg/kg [26, 27]. This is the first study investigating the anti-tumor potential of BI 853520 in different in vitro and in vivo models of human MPM.

Materials and methods

Cell culture

SPC111, SPC212, and M38K cell lines were initially established from human biphasic MPMs, kindly provided by Prof. R. Stahel (SPC111 and SPC212, University of Zurich, Zurich, Switzerland) and Prof. V.L. Kinnula (M38K,
University of Helsinki, Helsinki, Finland). The P31 epithelioid MPM cell line was kindly provided by Prof. K. Grankvist (University of Umea, Umea, Sweden). The non-malignant mesothelial cell line Met5a (ATCC CRL-9444) was purchased from the American Type Culture Collection. Meso and VMC primary cell lines were established at the Medical University of Vienna (ethics approval number: “THORAXBANK” 904/2009). Histological subtype distribution among these cell lines are listed in Table 1. Cells were cultured in RPMI-1640 or DMEM plus 10% fetal calf serum (FCS) (Sigma Chemical Co., St. Louis, MO), 100 U/ml penicillin, and 10 mg/ml streptomycin (Sigma Chemical Co., St. Louis, MO). Cell lines were kept at 37 °C in a humidified incubator with 5% CO₂.

Chemosensitivity assays

In order to assess the short-term effect of BI 853520 (Boehringer Ingelheim) on cell viability, total protein amount–based sulforhodamine B (SRB) assays were performed in 12 MPM cell lines and in the immortalized mesothelial line Met5a. Additionally, BI 853520 and cisplatin (Teva Hungary) combination treatments were done in one merlin-positive (SPC212) and one merlin-negative cell line (P31). SRB assays were executed as published previously [28]. Briefly, cells were seeded in 96-well plates 24 h before drug exposure to be afterwards treated with different concentrations of cisplatin and BI 853520 for 72 h. Regarding combination treatments, we calculated combination indices (CI) according to Chou and Talalay [29] with the CalcuSyn software (Biosoft, Ferguson, MO). CI values < 0.9, from 0.9 to 1.1, or > 1.1 indicated synergism, additive effects, or antagonism between BI 853520 and cisplatin, respectively.

Analysis of in vitro cell migration by time-lapse video microscopy

2D video microscopy measurements were performed and analyzed as previously described [30]. Briefly, cells were seeded in 24-well plates (Corning Incorporated, Corning, NY) and cultured in DMEM medium supplemented with 10% FCS. Medium was changed to CO₂-independent medium (Invitrogen, Carlsbad, CA) with 10% FCS and 4 mM glutamine, and cells were kept in a custom-designed incubator built around an inverted phase-contrast microscope (World Precision Instruments, Sarasota, FL). Every 5 min, images from three distinct neighboring microscopic fields were taken for at least 48 h. After 24 h of observation, BI 853520 was added and cells were finally observed for another 72 h. Individual cells were tracked for the first 24 h after treatment with a cell tracking program, their position parameters were extracted, and migrated distance was calculated as previously described [31].

Tumor cell spheroid assay

In order to obtain MPM cell line–derived spheroid cultures, 5 × 10³ MPM cells (SPC212 or P31) were seeded in triplicate in DMEM/Ham’s F-12 medium (Biochrom) in ultra-low attachment 24-well plates (Thermo Scientific). Medium was supplemented with 20 ng/ml basic fibroblast growth factor (FGF) (PeproTech), 20 ng/ml epidermal growth factor (Sigma), and 2% B27 supplement (Gibco). BI 853520 was added at 0.1 μM and 1 μM. Ninety-six hours following plating, spheroids in all wells were photographed. Spheres with a diameter above 100 μm were counted. Diameters were measured by using ImageJ software.

Table 1 Histological subtype, merlin status, and IC₅₀ values for each cell line

| Cell line | Histological subtype | Merlin status | IC₅₀ of BI 853520 (μM) |
|-----------|----------------------|---------------|------------------------|
| Met5a     | Immortalized mesothelial cell | –             | 9                      |
| Meso49    | Epithelioid MPM       | –             | 5.5                    |
| Meso53    | Biphasic MPM          | +             | 5.5                    |
| SPC111    | Biphasic MPM          | –             | 5.6                    |
| P31       | Epithelioid MPM       | –             | 5.9                    |
| VMC20     | Epithelioid MPM       | –             | 5.9                    |
| VMC23     | Epithelioid MPM       | –             | 5.8                    |
| M38K      | Biphasic MPM          | +             | 6.6                    |
| VMC40     | Biphasic MPM          | –             | 7.5                    |
| Meso62    | Sarcomatoid MPM       | –             | 8.8                    |
| SPC212    | Biphasic MPM          | +             | 10.2                   |
| VMC6      | Epithelioid MPM       | –             | 11.5                   |
| VMC12     | Epithelioid MPM       | +             | 11.3                   |
Western blot analysis

For merlin and E-cadherin expression analysis, subconfluent cultures of all 12 cell lines were processed. To determine the impact of FAK inhibition on cell signaling, SPC111, P31, SPC212, or M38K cells were seeded into 6-well plates and—after 24 h of recovery—treated with BI 853520 or solvent. Subsequently, cells were extracted in RIPA buffer (Fisher Scientific, Waltham, MA, Cat. No.: 3168890) containing protease inhibitor cocktail (Fisher Scientific, Cat. No.: 78430) to later separate proteins by SDS-PAGE. Proteins were blotted onto nitrocellulose membranes and immunostained with the following primary antibodies from cell signaling: merlin (#6995), E-cadherin (#3195), Erk (#9102), p-Erk (#9101), Akt (#9272), p-Akt (Tyr-397, #8556), and β-tubulin (#2128). For antibodies, a dilution of 1:1000 was applied, followed by horseradish peroxidase–coupled secondary antibody (Thermo Fisher Scientific) incubation and development by ECL Reagent (GE Healthcare, Dassel, Germany) with a developer machine (Curix60 AGFA Type 9462/106).

Analysis of tumor stem cell marker expression

For tumor spheroid formation, MPM cells were seeded as described above and treated with 0.1 μM and 0.5 μM BI 853520 for 4 days. Total RNA was isolated with TRizol and reverse transcribed with MMLV reverse transcriptase (Thermo Fisher Scientific) and random hexamer primers. The resulting cDNAs were analyzed using TaqMan gene expression assays on the Applied Biosystems 7500 Fast Real-Time PCR System (Assay IDs: ALDH1A1 Hs00946916; CD44 Hs01075854; GAPDH Hs02786624; Myc Hs01570247; NANOG Hs02387400; Oct4 Hs04260367; SOX2 Hs01053049; Thermo Fisher Scientific). Gene expression was calculated by the ΔΔC(T) method using GAPDH as reference gene.

Orthotopic in vivo MPM xenograft model

In order to develop orthotopically growing MPM tumors, two million P31 cells were inoculated into the chest cavity of 8-week-old female SCID mice from our colony. Animals were randomly stratified into treatment and control groups once tumor nodules had a macroscopically visible size (based on our preliminary experiments 28 days following tumor implantation). Regarding treatment, mice received solvent or 20 mg/kg BI 853520 (dissolved in methylcellulose) orally five times a week on consecutive days (one cycle with 5 days on and 2 days off treatment). Animals were weighed three times a week and the experiment was ended on the 20th day of treatment. Finally, MPM tumor nodules were harvested, weighed, and fixed in formalin and embedded in paraffin (FFPE) or stored as frozen tissue. All mentioned animal experiments were performed according to the ARRIVE guidelines [32] and to the animal welfare regulations of the host institutes (permission number: PEI/001/2574-6/2015).

Evaluation of apoptosis and tumor vascularization in vivo

Serial frozen sections were cut from each tumor. For the analysis of apoptosis, terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling (TUNEL) was accomplished according to the manufacturer’s instructions (Roche Diagnostics). DAPI was used to label nuclei and slides were scanned by TissueFAXS (TissueGnostics GmbH, Vienna, Austria). Apoptosis was quantified as the percentage of TUNEL-positive nuclei among DAPI-labeled ones. To analyze the effect of FAK inhibition on angiogenesis, consecutive frozen sections were stained for microvessels with CD31 (clone SZ31, Dianova). Intratumoral microvessel density analysis was performed by using the StrataQuest software (TissueGnostics, Vienna, Austria).

Assessment of tumor cell proliferation by Ki67 labeling

Ki67 immunohistochemistry was performed as described earlier [33]. Three-micrometer sections from formalin-fixed and paraffin-embedded (FFPE) tumor nodules were deparaffinized and rehydrated with decreasing alcohol concentrations. Following heat-induced antigen retrieval in citrate buffer (pH 6.0), slides were incubated with the Ki67 antibody (mouse mAb, Dako Cytomation, clone MIB-1, dilution 1:100) for 30 min. UltraVision LP detection system (Lab Vision Corporation, Fremont, CA) was used to detect antibody binding according to the manufacturer’s recommendations. 3-3-Diaminobenzidine (Dako) was applied for color development. Each analyzed slide was counterstained with Mayer’s hematoxylin (Sigma) and images were taken using a bright-field microscope (Axio Imager, Carl Zeiss). Labeling index was determined by using the automated image analysis application ImmunoRatio [34]. At least 2000 tumor cells were counted to obtain the mean percentage of Ki67-positive MPM tumor cells per sample.

Statistical analyses

In order to compare two groups, Mann-Whitney U tests were performed. Kruskal-Wallis and Dunn’s multiple comparison tests were used for more than two groups. P values below 0.05 were considered statistically significant. For all statistical analyses, the GraphPad Prism 5.0 software (GraphPad Inc., San Diego, CA) was applied.
Data accessibility

Data and commercially not available material is available from the corresponding authors upon reasonable request.

Results

Response to FAK inhibition in adherent MPM cell models in vitro is independent of merlin expression and histological subtype

In order to investigate whether histological subtype and merlin or E-cadherin expression influence the sensitivity of MPM cells to FAK inhibition in vitro, we determined the IC$_{50}$ values by performing SRB assays of adherently grown cells following 72 h of BI 853520 treatment (Fig. 1 and Table 1). None of the 12 MPM cell lines in our panel expressed E-cadherin (data not shown). All cell lines demonstrated IC$_{50}$ values above 5 μM including three cell lines with very low sensitivity (IC$_{50}$ values above 10 μM, Fig. 1b). In our panel of cell lines, sensitivity to BI 853520 showed no association with histological subtype or merlin expression (Supplementary Fig. 1).

BI 853520 does not synergize with cisplatin in vitro

Since certain FAK inhibitors demonstrated a synergistic effect with cisplatin in other malignant diseases [9], cell viability was also measured when BI 853520 was applied in combination with cisplatin. In these experiments, we used the relatively sensitive and merlin-negative P31 and the more resistant and merlin-expressing SPC212 cells. The CI index calculations demonstrate that at the majority of concentrations, only additive or even antagonistic interactions are achievable (Supplementary Fig. 2).

FAK inhibition reduces MPM cell motility in a cell type–dependent manner

Because FAK is a known regulator of actin remodeling and focal adhesion dynamics, we also measured the in vitro migratory activity in the presence of BI 853520.
The cell lines SPC111, SPC212, P31, and M38K were selected for the further experiments to represent both epithelioid and biphasic and merlin-expressing as well as merlin-negative subtypes. The average migrated distance of the four different MPM cell lines was measured in the first 24 h following treatment with BI 853520 or solvent (Fig. 2). Of note, BI 853520 showed an anti-migratory effect even at the 1 μM concentration which is way below the IC_{50} values for cell viability in three of the four cell lines. Interestingly, SPC212 cells with very low sensitivity in adherent growth assay demonstrated a strong migration inhibitory response. The cell line with the lowest baseline motility, i.e., P31, showed a slight increase in migration at this concentration.

**BI 853520 efficiently reduces FAK phosphorylation but not the activation of Akt, S6, or Erk**

In order to examine if FAK is activated in MPM cells and whether BI 853520 can interfere with FAK phosphorylation, we performed time-course immunoblot analyses in adherent cultures (Fig. 3 and Supplementary Fig. 3). While the FAK inhibitor led to a rapid and sustained decrease (i.e., from 30 min to 24 h) of Tyr397 phosphorylation in the four cell lines studied (SPC111, SPC212, P31, and M38K), we did not observe a sustained and consequent reduction in Akt, S6, or Erk phosphorylation. After 24 h of BI 853520 treatment, the FAK phosphorylation remained inhibited but there was no difference in the cells in downstream activation when compared to the 24-h solvent-treated controls.

**FAK inhibition interferes with MPM cell spheroid formation**

Because FAK inhibitors were previously found to have an impact on tumor-initiating cell populations [19], we performed spheroid formation assays by culturing SPC111, SPC212, P31, and M38K cells under serum-free and non-adherent conditions (Fig. 4). While all four cell lines readily formed spheroids after 96 h under control conditions, we observed a cell line–dependent significant reduction in spheroid numbers at concentrations lower than the IC_{50} values pertinent to adherent MPM cell growth. P31 cells were not capable of forming spheroids in the presence of 0.1 or 1 μM BI 853520. Of note, despite the significant reduction in spheroid numbers, the diameter of the spheroids was not affected by BI 853520 in SPC212 cells. Importantly, similar to the adherent cell cultures, 24-h FAK inhibition led to a decrease in the phosphorylation of Tyr397 in all four cell lines; however, no reduction in Akt, S6, or Erk phosphorylation was observed in spheroid cultures (Supplementary Fig. 4). Notably, treatment of MPM spheroids with 0.1 or 0.5 μM BI 853520 did not change the expression of the putative tumor stem cell markers SOX2, Nanog, CD44, ALDH1, c-myc, and Oct4 (Supplementary Fig. 5).
BI 853520 reduces growth, proliferation, and microvessel density of orthotopically growing human MPM xenografts in mice

In order to investigate whether the in vitro effects translate to in vivo inhibitory potential, an orthotopic MPM model was established by injecting P31 cells—the cell line with the strongest response to FAK inhibition in spheroid formation—into the thoracic cavity of immunocompromised SCID mice (Fig. 5). There was a significant reduction in the tumor load as quantified by the total tumor weight dissected from the thoracic cavity after 3 weeks of per OS treatment with 20 mg/kg BI 853520 in a schedule of 5 days on and 2 days off (Fig. 5a). Notably, BI 853520 treatment did not influence weight loss in the mice (Fig. 5b). Figure 5c shows representative hematoxylin and eosin (H&E) staining in xenograft tumors of either BI 853520- or solvent-treated mice. Mechanistically, the proliferation of tumor cells in the orthotopic tumors was decreased significantly in the BI 853520-treated animals (Fig. 6a, b); however, we did not observe increased apoptosis (as detected by TUNEL labeling) in these tumors (Supplementary Fig. 6). Importantly, vascularization of human MPM xenograft tumors was significantly reduced by BI 853520 treatment (Fig. 6c, d).

Discussion

In the current study, we demonstrate the impact of the FAK inhibitor BI 853520 on MPM tumor growth in 2D and 3D in vitro cultures and in an in vivo orthotopic model of human MPM. FAK is a multifunctional non-receptor protein tyrosine kinase, and its role in the progression of a variety of cancer types has now been abundantly demonstrated [35]. Importantly, inhibiting FAK by using small molecule inhibitors—such as BI 853520—that prevent the autophosphorylation seems to be a reliable approach [3, 11]. Relatively high IC₅₀ values were measured in our panel of cell lines in adherent cell viability assays. In contrast, BI 853520 treatment could interfere with spheroid formation at much lower concentrations. In support of this, another FAK inhibitor, namely PND-1186, was reported to selectively induce cancer cell apoptosis in a 3D environment [36]. Similarly, the FAK inhibitor VS-6062 demonstrated a greater effect in anchorage-independent growth of ovarian cancer cells when compared to cells in adherent cultures [18]. Hence, the significant 3D growth inhibitory effect of BI 853520 in human MPM cultures is important because there is accumulating evidence in drug
development suggesting that 3D tumor cell cultures (vs. 2D monolayers) more accurately model in vivo tumor complexity and thus provide more reliable data for subsequent in vivo and clinical testing [37, 38]. MPM progression is especially relevant in this regard because tumor spheroids are often present in the pleural effusions of MPM patients and contribute to tumor spread within the pleural cavity [39].

Cancer stem cells or tumor-initiating cells are defined as a small subpopulation of tumor cells with the potential to self-sustain and also to maintain tumor growth [19]. Previous studies in different tumor types (including MPM) [19] put forward the hypothesis that FAK inhibitors might preferentially target tumor-initiating cells that are capable of non-adherent growth and are thought to be enriched in tumor spheroids [19, 35]. BI 853520 treatment, however, did not alter tumor stem cell marker (SOX2 [40], ALDH1 [19, 40], NANOG [40], c-myc [40], CD44 [41], Oct4 [40, 41]) expressions of human tumor spheroids formed by different MPM cell lines. Based on our results, BI 853520 thus cannot be considered a selective inhibitor of tumor-initiating cells in human MPM spheroids.

FAK inhibitor sensitivity has been linked to merlin and E-cadherin expression in previous studies [18, 19, 25]. E-cadherin was found to be responsible for FAK inhibitor treatment failure in NF2-deficient MPM cells [25]. This is congruent with an in vitro study in bladder cancer, in which E-cadherin knockdown led to restoration of FAK inhibitor–mediated suppression of cancer cell invasion and migration [42]. Unfortunately, in our panel of cell lines, there were no E-cadherin-expressing MPM cells preventing us to study its impact on treatment responsiveness. With regard to NF2 expression, we found no significant difference in the adherent growth inhibitory potential of BI 853520; however, only four NF2-expressing cell lines were present in our panel.

The majority of MPM cell lines have considerable migratory activity, and integrin-mediated cell adhesion is reorganized during malignant progression [28, 30, 43]. In line with these data, in the current study, FAK inhibition led to a decrease in MPM migration in three out of four tested MPM cell lines. Since direct pharmacological targeting of integrins remains challenging, interfering with FAK as a potent downstream kinase might represent a viable approach to indirectly inhibit certain integrin functions.

Despite the relatively high BI 853520 IC50 values observed in our adherent cell growth assays, BI 853520
alone resulted in significantly decreased tumor load and tumor cell proliferation in an orthotopic model of human MPM. This is in line with previous studies using other FAK inhibitors in mouse models of human MPM [19]. Importantly, we could demonstrate that BI 853520 inhibits in vivo angiogenesis. This finding further supports the notion that FAK regulates endothelial cell migration and promotes angiogenesis and thus can serve as an additional target for anti-angiogenic cancer therapy [44]. The promising results from trials using first-line bevacizumab, cisplatin, and pemetrexed combinations in MPM patients underline the importance of anti-angiogenic therapies in this particular malignancy [45]. Importantly, FAK as a downstream element integrates proangiogenic signals received both via VEGFRs and integrin receptors, and as such, it might further increase the efficacy of VEGFR-directed therapeutic modalities [9, 46]. For example, in vivo studies in pancreatic neuroendocrine tumors indicated reduced incidence and number and size of liver metastases following the combination of another FAK inhibitor (OXA-11) with VEGFR2 blockade [9]. Additionally, a recent study on ovarian cancer mouse models showed that combining anti-angiogenic agents with FAK inhibitors clearly reduces tumor growth and, moreover, that FAK inhibitor treatment following anti-angiogenic therapy withdrawal inhibits tumor rebound [46].

Previous studies indicated that FAK inhibitors might enhance the effect of various chemotherapeutic agents such as paclitaxel and cisplatin in ovarian cancer and pancreatic neuroendocrine tumors, respectively [9, 47]. In the current study, two cell lines were tested in combination with cisplatin, but no synergisms were detected in adherent growth assays. Nevertheless, the combination of BI 853520 with other cytotoxic or targeted treatment modalities directly reducing MPM cell survival might prove to be efficient in future studies. For instance, we have recently reported that MPM cells co-express various FGFs and FGF receptors and, moreover, that inhibition of FGF receptor activity reduces MPM cell growth and migration and synergizes with chemo- and radiotherapy in vivo [48]. Because novel multitarget inhibitors have already been developed that can target certain tyrosine kinases and FAK simultaneously (e.g., PHM16, a novel dual FAK/FGFR2 inhibitor with potent anti-tumor and anti-angiogenic activities [49]), the simultaneous inhibition of FAK and FGFRs is a promising novel approach that should be investigated in human MPM models as well.

The recent phase 3 MAPS (Mesothelioma Avastin Cisplatin Pemetrexed Study) trial demonstrated increased OS in unresectable MPM from adding bevacizumab to standard-of-care chemotherapy [2], indicating that targeting the tumor vasculature might be an effective anti-MPM strategy. Despite this development, the prognosis of MPM remains dismal, and no additional molecularly targeted therapeutic option for MPM patients is available. The failure of the phase 2
placebo-controlled study of defactinib (VS-6063) in subjects with MPM (COMMAND), taken together with our finding that FAK inhibition can interfere with MPM spheroid growth in vitro and tumor growth and angiogenesis in vivo, highlights the importance of exploring combination therapeutic options to fully exploit the anti-tumor activity of FAK inhibitors in this fatal malignancy.

Conclusion

In conclusion, by investigating a large panel of MPM cell lines, we found that BI 853520, a novel, highly selective FAK inhibitor, has only limited activity in adherent 2D cell cultures, but it effectively inhibits the growth of 3D tumor spheroids. Moreover, BI 853520 blocked the growth of orthotopically growing human MPM xenografts in vivo. Additional studies are needed to further delineate the therapeutic value of BI 853520 in MPM.

Acknowledgements Open access funding provided by Medical University of Vienna. We thank Barbara Dekan and Violetta Piurko for competent technical assistance.

Authors’ contributions V.L., W.B., Mi.G., C.A., W.K., J.T., IC.W., D.B., and B.H. designed the study. MA.H., C.A., W.K., J.T., and W.B. provided materials. V.L., Z.V., J.O., I.K., T.G., Ma.G., and B.H. performed the experiments. V.L., Z.V., T.G., MA.H., TK., PS., J.T., D.B., and B.H. analyzed the data. V.L., PS., D.B., and B.H. wrote the manuscript, and W.B., Mi.G., and IC.W. edited the manuscript. All authors revised the manuscript prior to submission.

Funding This work was supported by Boehringer Ingelheim RCV GmbH, Vienna, Austria. Further support: the Hungarian National Research, Development and Innovation Office (K116295 and KFI_16-1-2017-0439, J.T.; K109626, K108465, KNN121510, and SNN114490, B.D.), the Semmelweis University University Start-Up grant (40148-11658, B.D.), the Vienna Fund for Innovative Interdisciplinary Cancer Research (B.D. and Mi.G.), the Anniversary Fund of the Austrian National Bank (No. 16912, Mi.G.), and the Austrian Science Fund (FWF, I2872 and I3522) (B.H. and V.L.). B.D. is the recipient of a postdoctoral fellowship of the Hungarian National Bank.

Compliance with ethical standards

Ethics approval and consent to participate As stated in the manuscript: All mentioned animal experiments were performed according to the ARRIVE guidelines [32] and to the animal welfare regulations of the host institute (permission number: PEI/001/2574-6/2015).

Conflict of interest Irene Waizenegger is an employee of Boehringer Ingelheim RCV GmbH & CoKG. The other authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References

1. Pistolesi M, Rusthoven J (2004) Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 126(4):1318–1329

2. Zalcman G, Mazerie J, Margery J, Grelitter L, Audigier-Valette C, Mom-Sibilot D, Molinier O, Corre R, Monnet I, Gouant V, Riviére F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebisty MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic I (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387(10026):1405–1414

3. Dunn KB, Heffler M, Golubovskaya V (2010) Evolving therapies and FAK inhibitors for the treatment of cancer. Anti Cancer Agents Med Chem 10(10):722–734

4. Shanthi E, Krishna MH, Arunesh GM, Venkateswara Reddy K, Sooriya Kumar J, Viswanadhan VN (2014) Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review. Expert Opin Ther Pat 24(10):1077–1100

5. Troyanovsky SM (1999) Mechanism of focal adhesion complex assembly. Curr Opin Cell Biol 11(5):561–566

6. Golubovskaya VM, Cance WG (2007) Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol 263:103–153

7. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6(1):56–68

8. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan JL (2009) Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 69(2):466–474

9. Moen I, Gebre M, Alonso-Camino V, Chen D, Epstein D, Q, Wei L, Shen Y, Zhang W (2017) Antitumor effect of focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis 6:26

10. Santos JC, Gan HK, Blagden SP, Plummer R, Arkenu HT, Ranson M, Evans TR, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean E, Brown J, Gibson D, Peddaredigari V, Murray S, Nebot N, Mazumdar J, Swartz L, Auger KR, Fleming RA, Singh R, Millward M (2016) A phase I, pharmacokinetic and pharmacodynamic study of GS2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol 27(12):2268–2274

11. Shimizu T, Fukuoka K, Takeda M, Iwata T, Yoshida T, Horobin J, Keegan M, Vaickus L, Chavan A, Padval M, Nakagawa K (2016) A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 77(5):997–1003

12. Kato T, Sato T, Yokoi K, Sekido Y (2017) E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells. Oncogene 36:5522–5531

13. Hirt UA, Braunger J, Schleicher M, Weyer-Czernilofsky U, Garay T, Juhasz E, Molnar E, Eisenbauer M, Czirok A, Dekan B, Laszlo V, Hoda MA, Dome B, Timar J, Klepetko W, Berger W, Hagedus B (2013) Cell migration or cytokinesis and proliferation: revisiting the “go or grow” hypothesis in cancer cells in vitro. Exp Cell Res 319(20):3094–3103

14. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27–55
30. Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozzas A, Kennessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Bricc L, Kern I, Rozman A, Popper H, Zochbauer-Muller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B (2015) Epigenetic down-regulation of integrin alpha7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. J Pathol 237(2):203–214

31. Hegedus B, Zach J, Czirik A, Lovey J, Viscek T (2004) Irradiation and Taxol treatment result in non-monotonous, dose-dependent changes in the motility of glioblastoma cells. J Neuro-Oncol 67(1–2):147–157

32. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8(6):e1000412

33. Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, Rozzas A, Renyi-Vamos F, Laszlo V, Grusch M, Filipits M, Scheed A, Jakopovic M, Samarzija M, Bricc L, Stancic-Rokotov D, Kern I, Rozman A, Dekan G, Klepetko W, Berger W, Glasz T, Dome B, Hegedus B (2015) Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. Br J Cancer 112(5):783–792

34. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J (2010) ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res : BCR 12(4):R56

35. Lee BY, Timpson P, Horvath LG, Daly RJ (2015) FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther 146:132–149

36. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, Popper H, Zochbauer-Muller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B (2018) Three-dimensional in vitro cell culture models of in ovarian cancer. JNCI: J Natl Cancer Instit 105(19):1485–1495

37. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Blum W, Pecze L, Felley-Bosco E, Wu L, de Perrot M, Schwaller B, Brosseau S, Assoun S, Nalte C, Steinmetz C, Gavan V, Zalcman G (2017) A review of bevacizumab in the treatment of malignant pleural mesothelioma. Future Oncol 13:2517–2546

38. Ali G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G (2013) Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. J Thorac Oncol 8(11):1389–1395

39. Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK (2016) FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 126(5):1885–1896

40. Kong DB, Chen F, Sima N (2017) Focal adhesion kinases crucially regulate TGFbeta-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin. OncoTargets Ther 10:1783–1792

41. Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK (2016) FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 126(5):1885–1896

42. Ali G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G (2013) Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. J Thorac Oncol 8(11):1389–1395

43. Ali G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G (2013) Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. J Thorac Oncol 8(11):1389–1395

44. Roy-Lazarraga M, Hodiivala-Dilke K (2016) Molecular pathways: endothelial cell FAK-A target for cancer treatment. Clin Cancer Res 22(15):3718–3724